Study type: Human research · Status: Verified against declared source

A retrospective study of Cerebrolysin in patients with moderate to severe traumatic brain injury: Cognitive and functional outcomes

2023

Study scale: An evident strength of the current study was the homogenous patient sample enrolled despite the considerable heterogeneity of TBI patients, allowing for an unbiased interpretation of the study results.

Abstract only: Open source record

Product or molecular entity relationships

  • Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

In this retrospective study, we aimed to evaluate the effects of the neurotrophic compound Cerebrolysin on executive, cognitive, and functional performance in patients with traumatic brain injury (TBI) with a highly severe disability level.

Methods

In this retrospective study, we aimed to evaluate the effects of the neurotrophic compound Cerebrolysin on executive, cognitive, and functional performance in patients with traumatic brain injury (TBI) with a highly severe disability level.

Scale or participants

An evident strength of the current study was the homogenous patient sample enrolled despite the considerable heterogeneity of TBI patients, allowing for an unbiased interpretation of the study results.

Key findings

In this retrospective study, we aimed to evaluate the effects of the neurotrophic compound Cerebrolysin on executive, cognitive, and functional performance in patients with traumatic brain injury (TBI) with a highly severe disability level.

Limitations and uncertainty

In this retrospective study, we aimed to evaluate the effects of the neurotrophic compound Cerebrolysin on executive, cognitive, and functional performance in patients with traumatic brain injury (TBI) with a highly severe disability level.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.